Retevmo (Selpercatinib)
- Medicine Name: Retevmo
- Generic Name: Selpercatinib
- Dosage Form & Strength: Capsules: 40/80 mg
- Manufactured By: Eli Lilly and Company
- Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
- Adult and pediatric patients aged 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
- Adult and pediatric patients aged 12 years and older with advanced or metastatic RET fusion +Ve thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
- Severe hepatic adverse reactions occurred in patients treated with selpercatinib capsules. Monitor ALT and AST prior to initiating Selpercatinib, every 2 weeks during the initial 3 months, then monthly thereafter.
- Hypertension occurred in patients, including Grade 3 and Grade 4 hypertension. Monitor ALT and AST before initiating retevmo capsules, every 2 weeks during the initial 3 months, then monthly thereafter.
- Selpercatinib can cause concentration-dependent QT interval prolongation. Assess patients who are at significant risk of having QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, and severe or uncontrolled heart failure.
- Evaluate the QT interval more frequently when retevmo 40 mg capsules is concomitantly used with strong and moderate CYP3A inhibitors or medicines known to prolong QTc interval.
- Serious events including fatal hemorrhagic events can occur with selpercatinib. Permanently interrupt selpercatinib therapy in such patients who are with life-threatening or severe hemorrhage.
- Impaired wound healing may appear in patients who receive medicines that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore, retevmo 80 mg capsules has the potential to adversely affect wound healing.
What documents are required to import RETEVMO to India?
RETEVMO (Selpercatinib) Capsules can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients id proof (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is RETEVMO available in India?
RETEVMO (Selpercatinib Capsules) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
RETEVMO can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of RETEVMO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9650877511 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for retevmo price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the RETEVMO (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Retevmo®?
Selpercatinib is Generic Name for the trade name drug Retevmo®.
What is the Manufacturer Name of Retevmo®?
Retevmo® is manufactured by Eli Lilly and Company.
Is Retevmo® approved by the FDA?
Yes, Retevmo® is approved by the FDA. Date of approval: May 8, 2020.
What is Retevmo®?
Retevmo is authorized for RET-positive metastatic non-small cell lung cancer (NSCLC) and advanced thyroid cancers.
What is the dosage and form of Retevmo® supplied?
Retevmo® is supplied as Capsules: 40/80 mg for oral administration.
What are the most common side effects due to Retevmo®?
Most common side effects due to Retevmo® include: lower platelet count, higher cholesterol levels, rash, lower salt (sodium) levels in the blood, constipation, lower calcium levels in the blood, dry mouth, diarrhea, higher creatinine levels (this measures kidney function), high blood pressure, tiredness and lower white blood cell count.
How much does Selpercatinib cost in India?
The selpercatinib cost in India is reasonable. In order to procure this kinase inhibitor authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Retevmo®?
Store at 20-25°C (68-77°F); excursions between 15°C and 30°C (59°F to 86°F) are permitted.
What are the Highlights of prescribing information for Retevmo®?
Click Here to download full retevmo prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.